Carlyle's $2.2bn sale of Nature's Bounty's Holland & Barrett business to a Russian investment fund is the latest sign of the private equity sector's continuing interest in the health and wellness space.
Private equity firm Carlyle Group reaps roughly half what it paid for Nature's Bounty Co. in a sale of the nutritional supplement and health and wellness firm's international retail chain and brand, Holland & Barrett.
Carlyle's £1.77bn ($2.2bn) sale of the Nature's Bounty business to a Russian billionaire entrepreneur's investment fund is the latest sign...
Des recherches montrent que l’asthme et le diabète de type 2 (DT2) sont liés au-delà du hasard, partageant des facteurs inflammatoires et métaboliques. Cette association souligne l’importance d’une surveillance accrue et d’une prise en charge adaptée pour prévenir les complications chez les patients
Avista VC acquires OTC CMO Trillium; FDA deputy commissioner Jones to open CRN conference; AG1 founder steps down, COO moves up to CEO; ChromaDex hires general counsel; Ajinomoto, Shiru partner to develop sweet proteins; and change at ingredient provider LBB helm.
Church & Dwight’s slower sales at retail in June-July than in January-May point to still slower results for rest of year. It doesn’t expect second-half help from gummy vitamin lines or give them a full vote of confidence for remaining in portfolio.
Unilever hopes to double the value of its product innovations this year, ultimately targeting as many as 12 innovations, each costing more than €100m, beginning in 2025, CEO Hein Schumacher says during 25 July earnings presentation.
Intensified competition in the dietary supplements market and consumers squeezed by cost-of-living pressures held back sales at Dermapharm's Arkopharma subsidiary in the first half. A leadership change, along with a renewed focus on commercial excellence, is hoped by Dermapharm to turn the business around.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
